Fintel on MSN

Travere Therapeutics (TVTX) price target increased by 16.06% to 50.45

The average one-year price target for Travere Therapeutics (NasdaqGM:TVTX) has been revised to $50.45 / share. This is an ...

Purespring announces publication of notable study highlighting an under recognised genetic driver of adult-onset FSGS, in particular in US and UK populations

Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five international databases predicts a substantial, previously underdiagnosed adult NPHS2 ...

Purespring Therapeutics: Purespring announces publication of notable study highlighting an under recognised genetic driver of adult-onset FSGS, in particular in US and UK ...

Population modelling study published in Kidney International ReportsAnalysis of over 1.2 million genomes from five international databases predicts a substantial, previously underdiagnosed adult NPHS2 ...
Zacks Small Cap Research on MSN

LGND: XOMA buy adds 100+ assets

By John Vandermosten, CFA NASDAQ: LGND | NASDAQ: XOMA In an April 27th press release, Ligand Pharmaceuticals, Inc. (NASDAQ: ...